NCT01388829View on ClinicalTrials.gov

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Healthy
Interventions
DRUG

Treatment A

150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot

DRUG

Treatment B

150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01388829 - Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532 | Biotech Hunter | Biotech Hunter